AGILE THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.38 USD | +1.20% |
|
-8.37% | -80.51% |
| Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
| Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
Presenter SpeechSushil Bhandaru (Analysts)Good morning, and welcome to the 40th Annual JPMorga...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -80.51% | 2.57M | |
| +5.22% | 109B | |
| +11.13% | 105B | |
| -0.38% | 22.25B | |
| -11.93% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.17% | 16.85B | |
| +3.12% | 13.76B | |
| +36.16% | 12.46B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Transcript : Agile Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-13-2022 07